Alpha1B adrenoceptor expression is a marker of reduced survival and increased tumor recurrence in patients with endometrioid ovarian cancer

Table 2 Distribution of adrenoceptor protein expression in patients with ovarian cancer according to clinical stage, chemotherapy received and chemotherapy failure

		Adrenergic receptor	Absent	Present	χ2	P
Clinical stage	1	α-1B	39 (65)	21 (35)	2.486	0.478
	2		12 (50)	12 (50)
	3		47 (59)	33 (41)
	4		4 (44)	5 (56)
	1	α-2C	17 (29)	41 (71)	6.014	0.111
	2		10 (42)	14 (58)
	3		38 (49)	40 (51)
	4		2 (25)	6 (75)
	1	β2	18 (37)	31 (63)	6.508	0.089
	2		4 (20)	16 (80)
	3		31 (42)	43 (58)
	4		5 (71)	2 (29)
Stage 1 vs other stages	Stage 1	α-1B	37 (63)	22 (37)	0.894	0.344
	Other stages		59 (55)	48 (45)
	Stage 1	α-2C	17 (29)	42 (71)	4.376	0.036
	Other stages		49 (45)	59 (55)
	Stage 1	β2	18 (36)	32 (64)	0.090	0.764
	Other stages		37 (39)	59 (61)
Chemotherapy regimen	Before surgery	α-1B	11 (58)	8 (42)	0.734	0.693
	After surgery		84 (57)	62 (43)
	Before surgery	α-2C	8 (42)	11 (58)	0.702	0.704
	After surgery		58 (40)	87 (60)
	Before surgery	β2	8 (47)	9 (53)	1.316	0.518
	After surgery		46 (36)	80 (64)
Chemotherapy resistance	Refractory	α-1B	8 (80)	2 (20)	2.647	0.266
	Resistant within 6 mo		4 (44)	5 (56)
	Responsive		72 (58)	52 (42)
	Refractory	α-2C	2 (25)	6 (75)	2.342	0.310
	Resistant within 6 mo		6 (60)	4 (40)
	Responsive		50 (41)	73 (59)
	Refractory	β2	5 (56)	4 (44)	1.010	0.604
	Resistant within 6 mo		4 (40)	6 (60)
	Responsive		40 (38)	64 (62)

Proportion of patients showing each adrenoceptor (percentage).